The GLP is committed to full transparency. Download and review our Annual Report.

‘Have and have nots’: Future of biotech is human modification

, | | November 28, 2018

[I]n the next decade, the phrase [“have and have nots”] might mean “modded or unmodded”—as in, “have you been modified?” With biotech advancements such as brain-implanted neural chips, stem cell research, and gene editing, enhanced humans could usher in a new phase of evolution.

I spoke with Dr. Amanda Mason, Assistant Director for Strategy and Planning at MESH Academy.

[PCMag:] What’s your vision of biotech’s future?

[Mason:]I see a wide use of CRISPR, which is a type of gene editing, to correct disease—especially in the blood, which is easier to do [than other tissue types]. Then, as the technology matures, we will see editing in other tissues, and a movement away from the existing focus on cancer treatments.

Related article:  Video: EU Parliament member calls for 'pragmatic' debate about crop gene editing in Europe

[PCMag:] Do you then see a threshold emerging of those “with mods” and those without? Essentially cyborgs versus those who, well, are the “basic bio model”?

[Mason:] I guess my interpretation is quite different from a black and white “have versus have not” scenario. With real consideration on the subject, I’ve realized the pace of these discoveries have been robust over these past few decades, and I hope for a continual gradual process of innovation. Through our work in biotech, I hope these breakthroughs keep being deployed to improve and save lives.

Read full, original post: This USC Innovator Explains How Biotech Can Enhance Humans

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend